Zafgen, Inc.

Vanderbilt University

Novartis Ag

Novartis Pharma Ag

Novartis Pharma Gmbh

Thomas Edward Hughes

James E Vath

Alan Cherrington

Edwin Bernard Villhauer

Boerk Balkan

David G Holmes

David Grenville Holmes

Börk Balkan

The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.

Methods of treating an overweight subject

The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.

Methods of treating ischemic organ damage and other disorders

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Methods of treating liver diseases

Methods of treating impaired wound healing

Methods of treating renal disease and other disorders

The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.

Methods of treating age related disorders

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.

Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g., a MetAP-2 inhibitor.

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.

Methods of treating an overweight or obese subject

The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.

Use of DPP-IV inhibitor to reduce hypoglycemic events

A method for improving glucose control by administering metformin in combination with a DPP-IV inhibitor to a patient in need thereof, in an amount sufficient to control the glucose level over an extended period of time.

Growing community of inventors

Boston, MA, United States of America

Thomas Edward Hughes